Ahmad El Kouzi, MD

Movement Disorders Specialist
Neurology
Accepting new patients
Call for an appointment
or

    About me

    Ahmad El Kouzi, MD, is an Assistant Professor of Neurology and Movement Disorders at Southern Illinois University School of Medicine. He earned a medical degree from Beirut Arab University in Lebanon and completed a residency in Neurology at Southern Illinois University School of Medicine. He completed fellowship training in Movement Disorders at the University of Florida.

    He is the recipient of the prestigious Smallwood Fellowship Award and a Recognition of Excellence Award by the Norman Fixel Institute for Neurological Diseases at the University of Florida. Dr. El Kouzi's special interest is in Deep Brain Stimulation to treat Movement Disorders including Parkinson's Disease, Essential Tremor and Dystonia. He is the first author on multiple peer reviewed journal papers and scientific abstracts related to Parkinson's Disease and Deep Brain Stimulation. 

    He provides care for patients with movement disorders and other neurological diseases at SIU Medicine in Springfield, Illinois. Dr. El Kouzi currently serves as the Director of the Parkinson's Disease Center at SIU Medicine and is the principal investigator on many clinical trials related to Parkinson's Disease.

    Gender

    Male

    Additional languages spoken

    Arabic,
    French

    Education & training

    Positions
    Assistant Professor of Clinical Neurology
    Director Parkinson's Disease Center
    Board Certifications
    American Board of Psychiatry and Neurology
    Medical School
    Beirut Arab University
    Residency
    Southern Illinois University, Springfield, IL (Neurology)
    Fellowship
    University of Florida

    Specialties

    Clinical locations

    Locations

    SIU Neuroscience Institute

    751 N. Rutledge St. Springfield, IL 62702 Suite 3100
    Mon - Fri: 8:00 am-4:30 pm

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Clinical trials

    Trial
    Neuroscience Institute

    324-ETD-202: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

    Active recruiting

    The primary objective of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in a monotherapy cohort.

    Trial
    Neuroscience Institute

    BK-JM-201: A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients with Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components

    Active recruiting

    The primary objective of this study is to determine the safety and tolerability of buspirone (administered at 2 different doses) and zolmitriptan in Parkinson's disease patients.

    Trial
    Neurology

    A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

    Active recruiting

    The primary objective of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in a monotherapy cohort.

    Trial
    Neurology

    Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

    Active not recruiting

    This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).